Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Michael R Migden"'
Autor:
Carrick Burns, Shelby Kubicki, Quoc-Bao Nguyen, Nader Aboul-Fettouh, Kelly M. Wilmas, Olivia M. Chen, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers, Vol 14, Iss 15, p 3653 (2022)
cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. Th
Externí odkaz:
https://doaj.org/article/f72e81260eeb496591a7433bee9b3b2b
Autor:
Sirunya Silapunt, Michael R. Migden, Leon Chen, Nader Aboul-Fettouh, Junsheng Ma, Jigar Patel
Publikováno v:
Australasian Journal of Dermatology. 63:36-42
PD-1 inhibitors are immunotherapeutic agents used in the treatment of advanced cutaneous squamous cell carcinoma (cSCC). This study aimed to determine the pooled objective response and disease control rates of patients with advanced cSCC treated with
Autor:
Wanxing Chai-Ho, Jenny H. Lee, Ignacio Melero, Andrew Haydon, Nikhil I. Khushalani, Jose Lutzky, Andrew F. Hill, Gregory A. Daniels, Muhammad Alamgeer, Ragini R. Kudchadkar, Dimitrios Colevas, Ann Silk, Piyush Sheladia, Daniel Brungs, Shui He, Praveen K. Bommareddy, Frances A. Collichio, Samantha Bowyer, Céleste Lebbé, Michael R. Migden, Danny Rischin, Jean-jaques Grob, Matthew G. Fury, Claudia Andreu-Vieyra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe prognosis for advanced and metastatic cutaneous squamous cell carcinoma (CSCC) remains poor for many patients with the disease despite approval of the anti-PD1 antibodies cemiplimab and pembrolizumab.1 2 RP1 is an oncolytic virus (HSV-1
Autor:
Sherrif F. Ibrahim, Benedetta Campanelli, Morganna Freeman, Medha Sasane, Sunandana Chandra, Michael L. Andria, Guilherme Rabinowits, Emily S. Ruiz, Jigar Desai, Nikhil I. Khushalani, Alex Seluzhytsky, Zhen Chen, Chieh I. Chen, Michael R. Migden
Publikováno v:
Future Oncology. 16:11-19
In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In 2
Publikováno v:
Future oncology (London, England). 17(35)
Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies,
Autor:
Matthew G. Fury, Siyu Li, Medha Sasane, Dirk Schadendorf, Nikhil I. Khushalani, Karl D. Lewis, Vera Mastey, Elizabeth Stankevich, Axel Hauschild, Jocelyn Booth, Michael R. Migden, Anne Lynn S. Chang, Suk Young Yoo, Chieh I. Chen, Leonel Hernandez-Aya, Emmanuel Okoye, Zhen Chen, Chrysalyne D. Schmults, Israel Lowy, Alexander Guminski, Brett G.M. Hughes, Danny Rischin, Alesha A. Thai, Annette M. Lim
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundTo provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Method
Autor:
Anne Paccaly, Israel Lowy, Michael R. Migden, John D. Davis, Danny Rischin, Ronda Rippley, Feng Yang, Matthew G. Fury, Elizabeth Stankevich, Kyriakos P. Papadopoulos
Publikováno v:
Advances in Therapy
Introduction This study outlined cemiplimab intravenous (IV) dosing strategy to move from body weight (BW)-based 3 mg/kg every-2-week (Q2W) dosing in first-in-human study (study 1423; NCT02383212) to fixed 350 mg every-3-week (Q3W) dosing, utilizing
Publikováno v:
Future oncology (London, England). 15(27)
Advanced cutaneous squamous cell carcinoma (cSCC) accounts for only 5% of all cases of cSCC but up to 60% of disease related deaths. Historically, this disease has lacked effective treatment options due to a combination of poor response rate, poor re
Publikováno v:
Dermatology Practical & Conceptual, Vol 11, Iss S2 (2021)
Dermatol Pract Concept
Dermatol Pract Concept
Cutaneous squamous cell carcinomas (cSCC) represent one of the most diagnosed non-melanoma skin cancers and its incidence is increasing globally. Whereas early stage and low risk cSCC is typically treated with surgery, and in some cases other localiz
Autor:
P.K. Bommareddy, A.D. Colevas, Danny Rischin, Jenny H. Lee, Andrew Haydon, Nikhil I. Khushalani, Wanxing Chai-Ho, Ragini R. Kudchadkar, Andrew F. Hill, M. Alamgeer, Frances A. Collichio, Gregory A. Daniels, Daniel Brungs, Jose Lutzky, P. Sheladia, C. Andreu-Vieyra, S. He, Samantha Bowyer, Michael R. Migden, Matthew G. Fury
Publikováno v:
Annals of Oncology. 32:S904